Improves access to lower-cost generic and biosimilar drugs.
Impact
A6209 represents a significant shift in how generic and biosimilar medications will be managed within state health programs. By requiring vendors to publish and maintain an up-to-date list of covered drugs in a readily accessible manner, the bill aims to enhance transparency and informed decision-making for enrollees. It also sets forth provisions ensuring that enrollees have easier access to generics and biosimilars by stipulating that certain prior authorization restrictions cannot apply, ultimately encouraging the use of lower-cost options.
Summary
Assembly Bill A6209 is an act aimed at improving access to lower-cost generic and biosimilar drugs for covered persons under the State Health Benefits Program, the School Employees Health Benefits Program, and the State Medicaid program in New Jersey. The bill establishes a preference for biosimilars when a provider prescribes a brand drug to an enrolled individual who has not previously been treated with it. Furthermore, it mandates that managed care organizations include these biosimilars on their formularies and offer them at more favorable costs than their brand-name counterparts.
Contention
While proponents of A6209 assert that it will reduce healthcare costs and increase patient access to essential medications, some concerns have been raised regarding provider autonomy. Some healthcare professionals may feel restricted by the mandate to prescribe biosimilars instead of branded drugs, even when they might believe that a brand drug is more appropriate for certain patients. Critics argue this may infringe on tailored patient care practices, stressing the importance of maintaining flexibility in provider choices in pharmaceutical treatments.
Requires health plan coverage to include generic drugs and biosimilars where the wholesale acquisition cost of such generic drugs or biosimilars is lower than the brand drug's wholesale acquisition cost.
To Mandate The Use Of Biosimilar Medicines Under Health Benefit Plans; To Require A Healthcare Provider To Prescribe Biosimilar Medicines; And To Improve Access To Biosimilar Medicines.